Compare US Global Jets ETF (JETS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? US Global Jets ETF trades at $25.81 (market cap $812.53M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 9.3× US Global Jets ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 27 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| JETS | SYRE | |
|---|---|---|
Market Cap | $812.53M | $7.52B |
Volume | 5,144,947 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $108.92 |
52-Week Low | $23.64 | $22.18 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS is trading at $26.80, down 0.81% with a bearish technical outlook indicated by moving averages. The ETF faces headwinds from rising fuel costs and geopolitical tensions, though strong travel demand provides some support. Recent news highlights underperformance compared to aerospace/defense ETFs, with fuel expenses surging 85% in May 2026 according to Reuters.
The outlook remains cautious due to fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term performance depends on fuel cost management and travel demand sustainability, with technical support at $26 providing a key level to watch.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
